Dashboard
Manage Tickers

HUMA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

benchmark-maintains-buy-on-humacyte-lowers-price-target-to-11
Benchmark Maintains Buy on Humacyte, Lower...
11/13/2025 18:33:29

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $14 to $11.

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
11/13/2025 13:44:06

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-announces-six-presentations-scheduled-for-veithsymposium-nov-18-22
Humacyte Announces Six Presentations Sched...
11/13/2025 13:08:37

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
11/12/2025 19:14:38

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-q3-eps-011-beats-016-estimate-sales-753000k-miss-922333k-estimate
Humacyte Q3 EPS $(0.11) Beats $(0.16) Esti...
11/12/2025 12:08:35

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
11/12/2025 12:05:51

earnings-scheduled-for-november-12-2025
Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

insights-ahead-humacytes-quarterly-earnings
Insights Ahead: Humacyte's Quarterly Earnings
11/11/2025 18:04:40

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
11/10/2025 18:14:14

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-presents-2-yr-results-from-v007-phase-3-clinical-trial-of-atev-in-av-access-for-hemodialysis-patients-at-asn-kidney-week-2025
Humacyte Presents 2-Yr Results From V007 P...
11/10/2025 13:10:42

– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups ...

humacyte-publishes-study--showing-its-bioengineered-vessel-symvess-demonstrated-comparable-short-term-outcomes-to-autologous-vein-grafts-in-treating-extremity-arterial-trauma-with-similar-results-for-patency-limb-salvage-and-infection-rates
Humacyte Publishes Study Showing Its Bioe...
10/30/2025 12:10:20

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

btig-maintains-buy-on-humacyte-lowers-price-target-to-6
BTIG Maintains Buy on Humacyte, Lowers Pri...
10/13/2025 12:06:07

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $7 to $6.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

humacyte-raises-60m-in-oversubscribed-registered-direct-offering-with-institutional-investors-company-has-agreed-to-sell-28436018-shares-of-its-common-stock-and-warrants-to-purchase-28436018-shares-of-common-stock-at-a-combined-price-of-211
Humacyte Raises $60M In Oversubscribed Reg...
10/07/2025 13:05:18

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
10/06/2025 18:01:20

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacytes-symvess-shows-100-limb-salvage-zero-infections-in-wartime-trauma-patients-in-ukraine-published-in-oxford-academics-military-medicine-journal
Humacyte's Symvess Shows 100% Limb Salvage...
10/06/2025 13:29:48

- Results published in Oxford Academic's Military Medicine Journal -- After up to 18 months of follow-up patients were obse...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/03/2025 17:06:08

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
09/30/2025 11:06:16

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-secures-us-patent-for-bioengineered-esophagus-composition-using-proprietary-regenerative-tissue-engineering-platform
Humacyte Secures U.S. Patent For Bioengine...
09/29/2025 12:16:30

– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for im...

russell-2000-hits-all-time-highs-8-stocks-power-small-cap-comeback
Russell 2000 Hits All-Time Highs: 8 Stocks...
09/18/2025 19:08:11

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION